Last reviewed · How we verify
Over-encapsulated efavirenz
Over-encapsulated efavirenz is a reformulation of the HIV reverse transcriptase inhibitor efavirenz designed to improve tolerability by reducing peak plasma concentrations and CNS exposure through modified-release encapsulation.
Over-encapsulated efavirenz is a reformulation of the HIV reverse transcriptase inhibitor efavirenz designed to improve tolerability by reducing peak plasma concentrations and CNS exposure through modified-release encapsulation. Used for HIV-1 infection (as part of combination antiretroviral therapy).
At a glance
| Generic name | Over-encapsulated efavirenz |
|---|---|
| Also known as | Over-encapsulated Sustiva |
| Sponsor | University of Minnesota |
| Drug class | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication by inhibiting reverse transcriptase. The over-encapsulation technology delays and reduces the rate of drug absorption, lowering peak concentrations and potentially reducing neuropsychiatric adverse effects associated with high CNS penetration while maintaining therapeutic efficacy.
Approved indications
- HIV-1 infection (as part of combination antiretroviral therapy)
Common side effects
- Dizziness
- Impaired concentration
- Insomnia
- Rash
- Nausea
- Headache
- Abnormal dreams
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Over-encapsulated efavirenz CI brief — competitive landscape report
- Over-encapsulated efavirenz updates RSS · CI watch RSS
- University of Minnesota portfolio CI